We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Verastem Inc | NASDAQ:VSTM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.19 | 1.97% | 9.82 | 9.82 | 9.87 | 9.835 | 9.67 | 9.67 | 8,333 | 15:56:20 |
From Apr 2019 to Apr 2024
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019 at 1:30 p.m. PDT in Beverly Hills, CA.
A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005067/en/
Verastem Oncology:John DoyleVice President, Investor Relations & Finance+1 781-469-1546jdoyle@verastem.comInvestors:Joseph RayneArgot Partners+1 617-340-6075joseph@argotpartners.com
1 Year Verastem Chart |
1 Month Verastem Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
